Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin in moderately severe to severe Alzheimer's disease
NCT03560245Phase 2Completed
- Sponsor
- Synaptogenix, Inc.
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bryostatin 20µg with Placebo (2 arms). Primary endpoints: Severe Impairment Battery Total Score at 13 weeks and Adverse Events at 15 weeks. Started Jun 2018; status: completed.
02
Drugs
bryostatin-1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03560245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560245.